iSERA Lifesciences Limited (BOM:534920)
India · Delayed Price · Currency is INR 143.90
0.00 (0.00%)
At close: Sep 10, 2026
iSERA Lifesciences Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | - | 28.66 | 0.21 | 0.01 | 0.03 | 0.01 |
Cash & Short-Term Investments | 28.66 | 28.66 | 0.21 | 0.01 | 0.03 | 0.01 |
Cash Growth | 13679.81% | 13679.81% | 1385.71% | -49.32% | 179.53% | -99.91% |
Accounts Receivable | - | 12.02 | 3.13 | - | - | - |
Other Receivables | - | 0.51 | - | - | - | - |
Receivables | - | 12.53 | 15.33 | - | - | - |
Other Current Assets | - | 2.04 | - | 0.53 | 0.48 | - |
Total Current Assets | - | 43.23 | 15.54 | 0.55 | 0.51 | 0.01 |
Other Long-Term Assets | - | - | 0 | - | - | - |
Total Assets | - | 105.62 | 15.54 | 0.55 | 0.51 | 0.01 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | - | 4.95 | 0.22 | 0.32 | - | - |
Accrued Expenses | - | 0.22 | - | - | - | - |
Current Unearned Revenue | - | - | - | 0.25 | 0.25 | - |
Other Current Liabilities | - | 1.36 | 0.24 | 0.3 | 0.17 | 0.06 |
Total Current Liabilities | - | 6.52 | 0.46 | 0.87 | 0.42 | 0.06 |
Long-Term Debt | - | 16.63 | 16.06 | 1.84 | 1.25 | - |
Other Long-Term Liabilities | - | - | - | 0 | - | - |
Total Liabilities | - | 23.15 | 16.52 | 2.71 | 1.67 | 0.06 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | - | 84.09 | 3.23 | 3.23 | 3 | 3.01 |
Retained Earnings | - | - | -4.21 | -5.4 | -4.17 | -3.06 |
Comprehensive Income & Other | - | -1.62 | - | - | 0.01 | - |
Total Common Equity | 82.47 | 82.47 | -0.98 | -2.16 | -1.16 | -0.05 |
Shareholders' Equity | 82.47 | 82.47 | -0.98 | -2.16 | -1.16 | -0.05 |
Total Liabilities & Equity | - | 105.62 | 15.54 | 0.55 | 0.51 | 0.01 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 16.63 | 16.63 | 16.06 | 1.84 | 1.25 | - |
Net Cash (Debt) | 12.03 | 12.03 | -15.85 | -1.83 | -1.22 | 0.01 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | 5.73 | 1.43 | -49.48 | -6.10 | -4.08 | - |
Filing Date Shares Outstanding | 2.1 | 8.41 | 0.32 | 0.32 | 0.3 | 20 |
Total Common Shares Outstanding | 2.1 | 8.41 | 0.32 | 0.32 | 0.3 | 20 |
Working Capital | - | 36.71 | 15.08 | -0.32 | 0.09 | -0.05 |
Book Value Per Share | 9.81 | 9.81 | -3.03 | -6.68 | -3.88 | -0.00 |
Tangible Book Value | 82.47 | 82.47 | -0.98 | -2.16 | -1.16 | -0.05 |
Tangible Book Value Per Share | 9.81 | 9.81 | -3.03 | -6.68 | -3.88 | -0.00 |